Catalina Capital Group LLC Buys 634 Shares of Novo Nordisk A/S (NYSE:NVO)

Catalina Capital Group LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,264 shares of the company’s stock after purchasing an additional 634 shares during the quarter. Catalina Capital Group LLC’s holdings in Novo Nordisk A/S were worth $367,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Natixis Advisors LLC boosted its position in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Versant Capital Management Inc acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $4,066,000. Finally, Zions Bancorporation N.A. increased its stake in Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 2.1 %

Shares of Novo Nordisk A/S stock opened at $82.64 on Tuesday. The company has a 50-day moving average of $93.56 and a two-hundred day moving average of $112.87. The stock has a market cap of $370.85 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Analysts Set New Price Targets

NVO has been the topic of several analyst reports. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.